A Research Guide for
Diabetes

Diabetes is diagnosed when blood sugar exceeds defined thresholds on any of three standard tests:

A diagnosis usually requires confirmation on a second test (different day) unless symptoms are obvious and the blood sugar is unambiguous. Prediabetes is not a harmless waiting room — it is a high-risk state and a strong signal to act.

After diagnosis, classification determines the right treatment path. Key tests include:

• Autoantibodies (GAD, IA-2, ZnT8, IAA): Positive results indicate autoimmune diabetes (Type 1 or LADA). Particularly important if the clinical picture is unclear.
• C-peptide: Measures how much insulin the body is still producing. Low C-peptide with positive antibodies confirms Type 1; preserved C-peptide with antibodies suggests LADA.
• Genetic testing: For suspected MODY — young onset, strong family history across generations, features that don’t fit Type 1 or Type 2. The Exeter MODY probability calculator can help guide referral.

Misclassification is common and consequential. An estimated 5–15% of adults diagnosed with Type 2 actually have LADA. Many MODY cases go unidentified for years. If treatment isn’t working as expected, revisiting the classification is a reasonable step.

• All adults 35+: Screened at least every 3 years
• Adults with risk factors (any age): Overweight/obesity, family history, history of gestational diabetes, polycystic ovary syndrome, high-risk ancestry (South Asian, East Asian, African, Hispanic, Pacific Islander)
• People of Asian descent: Screened at a lower BMI threshold (often from BMI 23 rather than 25), due to the “thin-fat” pattern of ectopic fat at lower body weights
• Children and teens: Screened if overweight with additional risk factors such as family history or high-risk ethnicity
• After gestational diabetes: Tested 4–12 weeks postpartum, then every 1–3 years lifelong

Type 2 diabetes almost always passes through a prediabetes phase — a period of abnormal but not yet diabetic blood sugar that lasts 5 to 15 years on average. During this window, standard blood tests (HbA1c, fasting glucose, or an oral glucose tolerance test) clearly identify the elevated risk.

What you gain by catching it early: The Diabetes Prevention Program (DPP) trial showed that structured lifestyle intervention in prediabetes reduced the risk of developing diabetes by 58%, and by 71% in people aged 60 and older. These benefits persisted for over 15 years. Metformin reduced risk by 31%. Newer medicines (GLP-1 agonists) show even stronger effects in high-risk populations. Prevention in the prediabetes window is among the most effective interventions in all of medicine.

What you lose by waiting: Every year of undetected diabetes increases the risk of irreversible damage to the eyes, kidneys, nerves, and cardiovascular system. By the time symptoms drive a person to the doctor (thirst, frequent urination, blurred vision), the disease is often well-established and some damage may already be present.

Type 1 diabetes is now understood as a disease that progresses through three stages. The autoimmune process begins months to years before any symptoms appear:

• Stage 1 (autoantibodies positive, normal blood sugar): The immune attack has begun but beta-cells still function normally. Detectable only by autoantibody testing. Can precede clinical diabetes by years to a decade or more.
• Stage 2 (autoantibodies positive, abnormal glucose tolerance): Beta-cell function is declining. An oral glucose tolerance test is abnormal. Still no symptoms. This stage can last months to years.
• Stage 3 (clinical diabetes): Symptoms appear — excessive thirst, urination, weight loss. Insulin treatment is needed. Up to 30% of children present in DKA (diabetic ketoacidosis) because the disease was not detected earlier.

What early detection buys for Type 1:

• Preventing DKA at onset. Children identified at Stage 1 or 2 through screening programs like TrialNet almost never present in DKA, because families are educated and monitoring. DKA at diagnosis is dangerous and associated with worse long-term outcomes.
• Access to disease-modifying treatment. Teplizumab (FDA-approved) can delay the progression from Stage 2 to Stage 3 by a median of ~2 years. You cannot receive this treatment if you do not know you are at Stage 2.
• Clinical trial access. Multiple trials are enrolling people at Stage 1 and 2 for therapies aimed at preserving beta-cell function. Early identification is required for enrollment.
• Emotional preparation. Families who know the diagnosis is coming handle the transition to insulin therapy with less crisis and better early management.

Who should be screened: TrialNet offers free autoantibody screening for relatives (ages 2.5–45) of people with Type 1 diabetes. A positive result does not mean diabetes is imminent — it means monitoring and preparation are warranted.

Most children who develop Type 1 diabetes have no family history, so screening only relatives misses them. Several programs now screen the general population:

• Fr1da (Bavaria, Germany) — the largest general-population program, having screened well over 100,000 young children. Among those found early who later progress, fewer than 5% present in DKA (versus ~20% in unscreened Germany).
• ASK (Colorado, USA) — screens children regardless of family history (often alongside celiac screening); it likewise brings DKA at diagnosis to under 5%.
• T1Detect (Breakthrough T1D) — a low-cost at-home finger-stick test you can order to check for the key autoantibodies, making screening accessible without a research-site visit.

A positive screen means monitoring and preparation — and, if Stage 2 is reached, eligibility for teplizumab to delay clinical diabetes.

If Type 2 runs in your family:

• Get screened (HbA1c or fasting glucose) starting at age 35, or earlier if you have risk factors. The test costs little and takes minutes.
• If prediabetes is found, treat it as an opportunity — not a waiting room. Ask about a structured prevention program (CDC-recognized Diabetes Prevention Programs exist in most areas and many are covered by insurance).
• Physical activity, weight management, and dietary changes started in the prediabetes phase are dramatically more effective than starting after diabetes is diagnosed.

If Type 1 runs in your family:

• Consider autoantibody screening through TrialNet for children and young adults in the family.
• A positive result does not mean panic — it means monitoring, access to teplizumab if Stage 2 is reached, and avoiding a DKA crisis.
• Most people with one autoantibody may never progress. Two or more autoantibodies carry a high lifetime risk of clinical diabetes.

The worry question: Is the knowledge worth the anxiety? Published data from TrialNet and similar programs consistently show that families value knowing, even when the news is concerning. The alternative — a child presenting in DKA at 3 AM in an emergency department — is worse. Knowledge enables planning. Planning enables better outcomes.

Modern guidelines recommend choosing medicines not just for glucose control, but for the cardiovascular and kidney benefits they offer. For many people with Type 2 diabetes, an SGLT2 inhibitor and/or a GLP-1 agonist is now part of first-line therapy alongside metformin.

Remission is defined by an internationally agreed consensus (ADA/EASD/Diabetes UK, 2021) as an HbA1c below 6.5% sustained for at least three months without any glucose-lowering medicine. It is a recovery state — not a permanent cure. The underlying genetic susceptibility remains, beta-cell capacity may continue to decline over time, and remission can be lost — especially if weight is regained. Ongoing monitoring is required even during remission. With that caveat clearly stated: for many people, remission represents years or even decades of life without active diabetes and its daily burden, and the metabolic benefits of the weight loss that achieves it persist even if glucose eventually rises again.

The dominant scientific model for Type 2 remission centers on ectopic fat — fat stored in the liver and pancreas. Excess liver fat drives insulin resistance and overproduction of glucose. This spills fat to the pancreas, where it stresses the beta-cells. When enough weight is lost (highly individual — it depends on each person’s “personal fat threshold”), liver and pancreatic fat fall, insulin resistance improves, and beta-cell function can recover.

This is not just theory. The landmark DiRECT trial showed that roughly one-third of participants achieved remission at two years through structured total diet replacement, and that success correlated with the amount of weight lost and, crucially, with the recovery of beta-cell function. Those whose beta-cells had been damaged beyond a critical point did not recover, regardless of weight lost — which is why acting early, while beta-cells are still capable of recovery, is so important.

• Shorter duration of diabetes: The strongest single predictor. The years right after diagnosis are the highest-yield window.
• Greater weight loss: In DiRECT, those who lost ≥15 kg had the highest remission rates (~86%). The threshold varies by person.
• Preserved beta-cell function: Measured by C-peptide. Those with more remaining function have the best odds.
• Lower baseline HbA1c / fewer medications: Suggest less advanced disease.

Remission is not guaranteed for anyone, and not achieving it is not failure. Even substantial weight loss that falls short of remission dramatically improves cardiovascular risk, blood sugar control, and quality of life.

Diet-based remission can fade over time. The DiRECT trial followed people for five years: about 36% were in remission at two years, but only about 13% at five years. Those who kept the weight off (about 6 kg on average) did best. The lesson is not that remission is futile — even time-limited remission, and the weight loss behind it, lower long-term risk — but that it requires ongoing support to maintain.

Medication-based control is not the same as a cure. GLP-1 and dual-agonist medicines work only while you take them. When they are stopped, studies show that much of the lost weight and the improvements in blood sugar and blood pressure return within about a year — for example, people regained roughly two-thirds of their lost weight after stopping semaglutide. This is not a personal failure; it reflects the biology of the disease. For most people these are long-term medicines, and any plan to stop or taper should be made with the medical team alongside a plan to protect the gains.

• Low-carbohydrate and ketogenic diets. These can produce high remission rates early on — some studies report well over half of participants in remission at one year — but, like total diet replacement, the numbers fall over time (toward roughly 1 in 8 by five years) unless the change is sustained. The best diet is the effective one you can actually keep.
• What happens in the real world. Outside of trials, remission is less common: a large real-world study of people starting a GLP-1 medicine found about 6% reached drug-free remission and about 18% reached remission while still on treatment. Honest expectations help — major benefit is common even when full remission is not.
• The gut microbiome (early research). Small studies of fecal microbiota transplant have shown short-term improvements in insulin resistance, but this is experimental and not a treatment option today.

The Diabetes Prevention Program (DPP) and its long-term follow-up demonstrated that structured lifestyle intervention — a coached program targeting 7% weight loss and 150 minutes/week of activity — reduced the risk of progressing from prediabetes to diabetes by 58%, and by 71% in people aged 60 and older. These benefits persisted for over 15 years of follow-up.

Metformin reduced risk by 31%, with benefits strongest in younger, heavier individuals. Newer GLP-1 and dual agonist medicines have shown even larger weight-loss effects and are being studied specifically for diabetes prevention in high-risk populations.

• Join a structured program: A recognized Diabetes Prevention Program (in person or digital) provides coaching, structure, and accountability for sustained weight loss of 5–7%.
• Build activity: 150 minutes/week of moderate movement plus 2–3 strength sessions. Muscle is where most glucose goes; building it changes metabolism.
• Choose a sustainable eating pattern: Mediterranean, lower-carbohydrate, or plant-predominant. The best pattern is the one you can maintain for years.
• Protect sleep: 7–9 hours; screen for sleep apnea if indicated. Sleep deprivation directly worsens insulin resistance.
• Consider medication: For higher-risk individuals, metformin or a GLP-1 alongside lifestyle change is worth discussing.

The first 1–3 months after a Type 2 diagnosis are a critical window. The priorities are:

• Confirm the type: Make sure Type 2 is the correct label. If anything is unusual, ask about antibody testing and C-peptide.
• Start safe treatment: Typically metformin as a foundation, with additional medicines chosen based on cardiovascular and kidney risk.
• First complication screening: Eyes, kidneys, feet, cardiovascular risk, and liver (FIB-4 for fatty liver disease).
• Recognize the remission window: If you are in the early years of Type 2, this is the highest-yield time to pursue remission. The conversation should begin now.
• Emotional adjustment: A new diagnosis is emotionally significant. Distress is normal and should be acknowledged.
• Education: Referral to a diabetes educator and dietitian. These are among the most underused and most valuable parts of care.

From diagnosis, diabetes care includes protecting the heart and kidneys — the two organs most damaged by diabetes over time:

• Blood pressure: Target < 130/80. ACE inhibitors or ARBs are preferred, especially with any kidney involvement.
• Cholesterol: A statin for most adults with diabetes, with intensity based on overall risk.
• SGLT2 inhibitors: Proven to protect the heart (reduce heart failure hospitalization) and slow kidney disease progression, independent of glucose-lowering.
• Finerenone: A newer agent for kidney and heart protection in diabetes with kidney disease; works alongside existing treatments.
• Antiplatelet therapy: Aspirin for secondary prevention; discuss with your team for primary prevention based on individual risk.

This is the highest-effort period: structured weight loss for Type 2, technology optimization for Type 1, supervised medication changes, and habit building. The three proven routes to substantial weight loss — any of which can support remission — are covered in detail in the following sections:

• Total diet replacement — formula-based programs producing rapid, supervised weight loss
• GLP-1 or dual agonist medicines + lifestyle change — pharmacological appetite reduction combined with behavioral support
• Metabolic surgery — for those who meet criteria, the most durable single intervention

These are not competing religions. They are tools, and the right choice depends on a person’s health, preferences, access, and discussion with their medical team. Some people combine elements from more than one approach.

Rapid weight loss costs muscle unless actively protected. Two essentials:

• Resistance training: 2–3 sessions per week. This is the single most effective defense against lean mass loss.
• Adequate protein: During active weight loss, aim for 1.2–1.6 g/kg body weight, spread through the day. Older adults should be especially careful not to under-eat protein.

Total diet replacement (TDR) means replacing all regular food with nutritionally complete formula products (shakes and soups, typically ~800 kcal/day) for a set period, usually 8–12 weeks, followed by a carefully structured food reintroduction and then long-term weight maintenance support.

The DiRECT trial is the landmark evidence: at one year, 46% of participants achieved remission; at two years, 36% sustained it. Those who lost ≥15 kg achieved remission rates of ~86%. Five-year follow-up data showed that approximately 13% of intervention participants remained in remission at five years overall, and approximately 20% among those who completed follow-up — a rate that rose sharply in those who maintained substantial weight loss. The honest picture: most people regain some weight and some lose remission, but even those who did had years of better metabolic health and lower medication burden. The UK NHS now offers this as a funded program (Path to Remission) for eligible adults.

Total diet replacement is not a do-it-yourself undertaking. It requires medical supervision for several critical reasons:

• Medication adjustment: Glucose-lowering medicines (especially insulin and sulfonylureas) must be reduced promptly to prevent dangerous hypoglycemia as blood sugar drops with weight loss.
• SGLT2 inhibitor risk: Combining an SGLT2 inhibitor with a very-low-calorie intake raises the risk of euglycemic ketoacidosis. The SGLT2 inhibitor is typically stopped before beginning TDR.
• Blood pressure medicines: May also need reduction as weight falls.
• Nutritional monitoring: Electrolytes and other markers need periodic checking.

The hardest part of any weight-loss intervention is keeping the weight off. Successful programs include:

• Gradual, structured food reintroduction over several weeks after the formula phase
• Long-term low-intensity support (regular check-ins, group support, digital coaching)
• A defined “weight-regain rescue plan” — agreed with the team in advance — so that early weight regain triggers action before blood sugar rises

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, and others) and the newer dual agonists (tirzepatide, which targets both GIP and GLP-1 receptors) work through several complementary mechanisms:

• Reduce appetite by acting on brain centers that regulate hunger and satiety
• Slow gastric emptying, which improves post-meal glucose and extends fullness
• Enhance insulin secretion in a glucose-dependent manner (low hypoglycemia risk)
• Produce substantial, sustained weight loss — in trials, 15–20%+ of body weight with the most effective agents

These medicines also have proven cardiovascular benefits (GLP-1 agonists reduce major cardiovascular events). Dual agonists show the largest combined weight-loss and glucose-improvement effects of any current medicines.

• Side effects: Nausea is common initially and usually improves with time and dose escalation. Vomiting, diarrhea, and constipation can occur. Rare but serious: pancreatitis, gallbladder disease.
• Muscle preservation: As with any rapid weight loss, resistance training and adequate protein are essential to protect lean mass.
• Cost and access: These medicines are expensive without coverage. Prior authorization is common. Manufacturer savings programs exist for some patients.
• Long-term use: Current evidence suggests that weight often rebounds when the medicine is stopped. For many, these may be long-term or maintenance-phase tools, combined with lifestyle change.
• Combination with other approaches: GLP-1 or dual agonists can be combined with structured lifestyle programs for potentially greater effect.

The incretin field is moving quickly. Several newer medicines go beyond today's semaglutide and tirzepatide — some are already approved, others are in late-stage trials. Most early data are in obesity; type-2-diabetes approvals for several of these are still pending. Ask your clinician what is actually available and appropriate for you.

• Orforglipron (Foundayo) — the first oral, non-peptide GLP-1 pill, taken any time of day with no food or water restrictions. FDA-approved for obesity in April 2026; a type-2-diabetes approval is still pending (filed in many countries). Could greatly simplify access compared with injections.
• Oral semaglutide, higher dose (oral Wegovy 25 mg) — FDA-approved for weight management in December 2025; a stronger oral option than the older 14 mg tablet (Rybelsus) used for diabetes.
• Retatrutide — a triple agonist (GLP-1 + GIP + glucagon). In the Phase 3 TRIUMPH-1 trial it produced roughly 25–30% average weight loss at the higher doses — approaching surgery-level results. Still investigational; a regulatory filing is expected around late 2026.
• CagriSema (semaglutide + cagrilintide) — pairs a GLP-1 with an amylin medicine; ~23% weight loss in obesity (REDEFINE 1) and strong HbA1c lowering in type 2 diabetes (REIMAGINE 2). FDA application for obesity filed December 2025; not yet approved.
• Survodutide (GLP-1 + glucagon), amycretin (an oral GLP-1/amylin combination), and petrelintide (a long-acting amylin) — all in clinical trials, extending the incretin toolkit further.

What did not work: Pfizer's oral GLP-1 pill danuglipron was discontinued in April 2025 after a case of liver injury — a reminder that not every pipeline drug reaches the clinic.

Metabolic (bariatric) surgery — principally gastric bypass and sleeve gastrectomy — produces the most sustained weight loss of any current intervention and has the highest long-term remission rates for Type 2 diabetes. Randomized trials comparing surgery to medical therapy alone consistently show superior diabetes outcomes with surgery, with remission rates of 30–60% maintained at 5+ years depending on the procedure and baseline factors.

Surgery also improves cardiovascular risk factors, reduces sleep apnea, and has shown reduced mortality in observational studies. Effects go beyond simple weight loss — surgery appears to change gut hormones, bile acid metabolism, and the microbiome in ways that independently improve glucose metabolism.

• Standard criteria: BMI ≥ 35 with diabetes, or BMI ≥ 40 regardless. Guidelines are evolving toward lower thresholds.
• Expanded criteria: Some guidelines now consider BMI ≥ 30 with Type 2 diabetes that is difficult to control.
• Asian-specific thresholds: Lower BMI cutoffs (often 27.5–30) are used, reflecting the different relationship between BMI and metabolic risk in Asian populations.
• Best outcomes: Earlier in the course of diabetes, with more preserved beta-cell function.

Surgery commits a person to:

• Lifelong nutritional supplementation (vitamins and minerals, especially B12, iron, calcium, vitamin D)
• Regular follow-up with a bariatric team
• Permanent dietary changes (smaller portions, specific food intolerances)
• Ongoing complication screening (even with remission, monitoring continues)

The decision is a significant one, best made with a multidisciplinary bariatric team after full evaluation.

As weight drops and blood sugar improves, diabetes medicines must be reduced — but this is a supervised process, not a personal decision:

• Insulin and sulfonylureas are reduced first, often proactively at the start of a weight-loss program, because they cause hypoglycemia.
• SGLT2 inhibitors may be stopped during very-low-calorie diets due to ketoacidosis risk.
• Metformin is typically the last to go and may be kept for its broader metabolic benefits even if glucose normalizes.
• The team leads: Every step follows a pre-agreed plan between you and your clinician.

Keeping remission is harder than reaching it. The biology actively resists sustained weight loss through hormonal changes (increased hunger hormones, decreased satiety signals, reduced metabolic rate). Successful maintenance requires:

• Ongoing low-intensity support (regular check-ins, group or digital programs)
• A pre-agreed “weight-regain rescue plan” that triggers early action
• Continued activity and dietary awareness
• Acceptance that re-intensification may be needed, and that this is a normal part of the process, not failure

Medicines such as GLP-1 agonists can serve as maintenance tools for some people. The best maintenance plan is one arranged at the start, while motivation is high.

Whether in remission or managing ongoing diabetes, long-term living means:

• Lifelong complication screening on schedule (eyes, kidneys, feet, cardiovascular)
• Adapting the plan as life changes (new jobs, aging, pregnancy, other health conditions)
• Recognizing that re-intensification is a normal, expected rhythm — not failure
• Sustaining the emotional and social supports that make daily management possible
• Staying current with evolving treatment options

Heart disease is the leading cause of death in people with diabetes. The risk is driven by the combination of high glucose, high blood pressure, abnormal cholesterol, and insulin resistance. Management includes:

• Blood pressure control to < 130/80 (ACE inhibitor or ARB preferred)
• Statin therapy for most adults with diabetes
• SGLT2 inhibitors (proven to reduce heart failure hospitalization)
• GLP-1 agonists (proven to reduce major adverse cardiovascular events)
• Antiplatelet therapy when indicated

Kidney disease develops silently in many people with diabetes. Screening (annual eGFR + urine albumin-to-creatinine ratio) is essential because early treatment dramatically slows progression:

• ACE inhibitors / ARBs: First-line protection for kidney disease in diabetes
• SGLT2 inhibitors: Major trials (CREDENCE, DAPA-CKD) showed significant slowing of kidney disease progression
• Finerenone: A non-steroidal mineralocorticoid receptor antagonist with proven kidney and heart benefits in diabetes (FIDELIO-DKD, FIGARO-DKD)
• GLP-1 medicines: Semaglutide slowed kidney-disease progression by 24% in the FLOW trial (2024), adding a fourth protective pillar alongside ACE/ARB, SGLT2 inhibitors, and finerenone
• Blood pressure and glucose control remain foundational

On the horizon: endothelin-receptor blockers such as atrasentan reduced kidney damage in studies but are not yet approved for this use.

Diabetic retinopathy is treatable if caught early, which is why regular dilated eye exams are essential. Risk increases with duration of diabetes and degree of glucose and blood-pressure control. Modern treatment includes laser therapy and anti-VEGF injections — including the newer bispecific faricimab (Vabysmo) — that can preserve and sometimes improve vision.

What's new:

• A pill that protects the retina. In the LENS trial (2024), the long-used cholesterol drug fenofibrate cut the progression of early retinopathy by about a quarter — a simple oral option to slow eye disease, confirming earlier signals from the FIELD and ACCORD studies.
• AI screening at the point of care. Autonomous AI systems can now read retinal photos and flag who needs an eye specialist — including handheld-camera systems (e.g., AEYE-DS, cleared in 2024) that bring screening into primary-care offices and underserved areas.
• Toward fewer injections. Researchers are testing eye gene therapies (such as RGX-314 and 4D-150) designed to deliver anti-VEGF from a single treatment for years, and long-acting steroid implants (Iluvien) for persistent macular swelling — all aiming to reduce the burden of frequent injections.

Peripheral neuropathy (numbness, tingling, pain in feet and hands) affects many people with long-standing diabetes. Combined with reduced blood flow, it raises the risk of foot ulcers and, in severe cases, amputation. Daily self-checks, properly fitting shoes, annual professional foot exams, and prompt attention to any wounds or changes are the foundation of prevention.

Alpha-lipoic acid has some evidence for easing neuropathic pain symptoms (see Supplements section). Medications such as gabapentin, pregabalin, and duloxetine are used for neuropathic pain management.

When pills aren't enough: for severe painful neuropathy that doesn't respond to medication, high-frequency (10-kHz) spinal cord stimulation — a small implanted device (Nevro Senza, FDA-approved for this use in 2021) — relieved pain substantially in trials, and notably about two-thirds of patients also showed measurable improvement in nerve function on examination, hinting at benefit beyond simply masking pain. (A newer oral nerve-pain medicine, mirogabalin, is approved in Japan and parts of Asia but not in the US or Europe.)

Diabetes can also affect the “automatic” nerves that run the heart, blood pressure, bladder, and digestion — called autonomic neuropathy. One important form is gastroparesis, in which the stomach empties too slowly, causing nausea, bloating, early fullness, and unpredictable blood sugars (because food and insulin no longer line up).

Management starts with the basics: improving glucose control, eating smaller and lower-fat/lower-fiber meals, and reviewing medicines that slow the stomach (notably GLP-1 medicines, which may need adjusting). When needed, prokinetic medicines (such as metoclopramide) and anti-nausea drugs help; for severe cases, a gastric “pacemaker” (gastric electrical stimulation) is an option. A newer prokinetic, relamorelin, improved symptoms and stomach emptying in mid-stage trials but is not yet approved. Tell your team about persistent nausea or fullness — gastroparesis is treatable and often missed.

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) is extremely common in Type 2 diabetes. A simple FIB-4 score calculated from routine blood results can estimate the risk of significant liver scarring. For those with advanced disease (MASH with fibrosis), weight loss and the approved liver-directed therapy resmetirom (Rezdiffra) are options.

New — a diabetes/weight medicine now treats the liver disease too. In August 2025 the FDA approved semaglutide (Wegovy) for MASH with moderate-to-advanced fibrosis (the ESSENCE trial showed MASH resolved in about 63% of treated patients). This makes a GLP-1 medicine the first that can address the diabetes/weight and the liver disease together. Several other agents — tirzepatide, survodutide, the FGF21 medicines (efruxifermin, pegozafermin), and lanifibranor — are in clinical trials for MASH.

Exercise improves insulin sensitivity, lowers blood sugar, supports weight management, reduces cardiovascular risk, and improves mood and energy. Muscle is where most glucose is disposed of, so building it through resistance training directly changes the metabolic equation. The targets:

• Aerobic: 150+ minutes/week of moderate-intensity activity (brisk walking, cycling, swimming)
• Resistance: 2–3 sessions/week targeting major muscle groups
• Break up sitting: Every 30 minutes of sitting, stand or move briefly — this has its own glucose benefit
• Start where you are: Any increase in movement from baseline helps. A 10-minute walk after meals measurably lowers post-meal glucose.

• Hypoglycemia risk: People on insulin or sulfonylureas may need to adjust doses around exercise. The team should provide specific guidance.
• Foot care: Inspect feet before and after exercise if neuropathy is present. Proper footwear is essential.
• Heart risk: For people with known or suspected heart disease, a graded approach with medical clearance is appropriate.
• Type 1 specifics: Exercise can both lower and raise blood sugar depending on type and timing. A CGM is particularly valuable for learning individual patterns.

• No single “diabetes diet”: Several evidence-backed patterns work — Mediterranean, lower-carbohydrate, plant-predominant, DASH. The best one is the one you can sustain.
• Adequate protein, spread through the day: Supports satiety, preserves muscle. During weight loss, aim for 1.2–1.6 g/kg.
• Choose carbohydrates with fiber: Whole grains, beans, lentils, vegetables, and fruit raise glucose more slowly than refined starch and sugar.
• Cut sugar-sweetened drinks first: Rapid glucose delivery with no satiety — for many, the single highest-value dietary change.
• Use healthy fats: Olive oil, nuts, seeds, and fatty fish support heart health.
• Mind meal timing: Eating earlier and avoiding heavy late-night eating fits the body’s natural rhythms. Time-restricted eating (10–12 hour window) can help some people.

• Type 2: For weight loss and remission, structured approaches (Parts above) apply. For everyday control, a sustainable pattern with calorie awareness, good protein, and fiber-rich carbohydrate.
• Type 1: Carbohydrate counting is the central skill — matching mealtime insulin to carbohydrate eaten. The goal is flexible, enjoyable eating made safe by accurate dosing, not a restrictive diet.
• Children and teens: Healthy growth and a positive relationship with food are the priority, not restriction. Watch for disordered eating, which is particularly dangerous in diabetes.
• Older adults: Adequate protein and enough total food to prevent muscle loss and frailty take priority over aggressive restriction.

Diabetes distress is the worry, frustration, and exhaustion from the relentless demands of self-management. It affects an estimated one-third to one-half of people with diabetes at some point. It is not a mental illness or a weakness — it is a rational response to a genuinely demanding situation. It also measurably worsens blood sugar by eroding the energy for daily management.

Burnout is what distress becomes when left unaddressed: pulling back from management, skipping checks, missing doses, avoiding appointments. It is common and recoverable. The response is not more pressure — it is simplifying the regimen, easing targets with a clinician’s agreement, reconnecting with support, and treating the underlying distress.

Depression is also more common in people with diabetes, and the relationship runs both ways. Both diabetes distress and depression should be screened for using brief validated questionnaires (standard part of good diabetes care).

• Structured education: Knowing what to do reduces fear; diabetes education reduces distress as well as HbA1c.
• Psychological support: Cognitive behavioral therapy and related approaches, ideally with someone experienced in diabetes.
• Peer connection: Talking with others who live with diabetes reduces isolation and offers practical wisdom.
• Reducing the daily load: Technology, simplified regimens, and shared responsibility within a family all lighten the burden.
• Self-compassion: Aiming for “good enough, most of the time” is both kinder and more effective than perfection.

Diabetes is lived by a household, not only an individual. Family involvement — shared meals, shared activity, shared understanding — improves outcomes, especially for children and teens. But involvement must be supportive rather than policing; constant monitoring and criticism create conflict and shame. For families of a child with diabetes, caregivers need their own support, rest, and the chance to share responsibility.

Blood sugar should be brought to target before conception — the earliest weeks of pregnancy are when high glucose carries the most risk. Several common medicines must be stopped before pregnancy (SGLT2 inhibitors, statins, certain blood-pressure medicines such as ACE inhibitors and ARBs, GLP-1 medicines, and finerenone). Insulin is the mainstay of treatment in pregnancy. During pregnancy, glucose targets are tighter and technology support is especially valuable for Type 1. The most important step is a preconception conversation with the diabetes team.

Gestational diabetes (GDM): Women who develop GDM have a substantially increased lifetime risk of Type 2 diabetes — published estimates range from 50% to over 70% within 10–25 years. Guidelines recommend glucose testing 4–12 weeks postpartum and then every 1–3 years for life. Lifestyle intervention after GDM is one of the highest-yield prevention opportunities in all of diabetes care. This risk also applies to the child, who should be monitored for metabolic risk factors as they grow.

Children need family-centered care, a school plan, and the chance to live a full childhood. Type 2 in young people tends to be more aggressive than in adults, with faster beta-cell decline. The transition from pediatric to adult care (late teens/early twenties) is a known point of vulnerability where control often slips — it deserves deliberate planning and a supported handover.

In older age, priorities shift toward quality of life, independence, and avoiding hypoglycemia. Glucose targets are appropriately relaxed, complex regimens are simplified, and attention turns to preventing falls, preserving muscle, ensuring adequate nutrition, and screening for depression and cognitive changes.

Illness raises blood sugar and ketoacidosis risk. Key rules:

• Do not stop insulin during illness — background insulin is still needed
• Check glucose more frequently
• Check ketones if at risk (especially Type 1 and SGLT2 inhibitor users)
• Stay hydrated
• Know the warning signs for urgent care (DKA symptoms, prolonged vomiting, inability to keep fluids down)
• Some medicines (SGLT2 inhibitors) are often paused during significant illness

Low blood sugar is the most common acute danger for people on insulin or sulfonylureas. Everyone affected — and people around them — should know:

• Symptoms: Shakiness, sweating, confusion, irritability, hunger
• Treatment: Fast-acting carbohydrate (glucose tablets, juice), recheck, then a longer-acting snack
• Severe lows: When a person cannot safely swallow, glucagon rescue is used. Family and close contacts should be trained in advance.
• Prevention: A CGM with low alerts is a major safeguard. Frequent or severe lows mean the plan needs adjusting.

Type 1 diabetes is an autoimmune disease in which the body’s immune system destroys the insulin-producing beta-cells. It can appear at any age (not just childhood), and it requires lifelong insulin replacement. Without insulin, the body cannot use glucose and begins producing ketones, which can lead to diabetic ketoacidosis — a medical emergency.

After diagnosis there is often a “honeymoon phase” where remaining beta-cells still function somewhat and insulin needs are temporarily lower. This period is now recognized as a window for treatments that may prolong remaining beta-cell function.

The three stages of Type 1

Type 1 is now understood as a disease that progresses through identifiable stages before symptoms appear:

• Stage 1: Two or more autoantibodies are present, but blood sugar is still normal. No symptoms. The autoimmune process has begun.
• Stage 2: Two or more autoantibodies plus abnormal glucose tolerance (impaired fasting glucose or abnormal OGTT). Still no clinical symptoms. This is the stage where teplizumab can delay progression.
• Stage 3: Clinical Type 1 diabetes — symptoms are present and insulin treatment is needed.

Identifying Stage 1 or 2 before symptoms appear matters because it allows monitoring to prevent DKA at onset and opens the door to disease-modifying treatment. TrialNet (trialnet.org) offers free autoantibody screening for relatives (ages 2.5–45) of people with Type 1 diabetes. A positive result does not mean the person will develop diabetes soon, but it allows the family and medical team to plan ahead.

• Time in range, not just HbA1c: The international consensus recommends > 70% time in range (70–180 mg/dL) with < 4% time below range. For young children and pregnancy, targets are adjusted.
• Technology as the standard: CGM and automated insulin delivery are the largest single improvement available for most people on insulin (see Technology section).
• Flexible eating: Carbohydrate counting allows matching insulin to food, enabling a full, unrestricted diet. Restrictive diets are specifically discouraged in children.
• Psychosocial support: Diabetes distress, burnout, and the burden of relentless self-management are core care priorities.

Diabetes management in children prioritizes normal growth, development, and the chance to be a child. Key considerations:

• Avoiding severe hypoglycemia, particularly in very young children
• School plans and educator training for insulin and glucagon administration
• Age-appropriate transfer of self-management skills as children grow
• Screening for eating disorders, which carry particular danger when combined with insulin
• Family-centered care that avoids making the child responsible for everything too early

A CGM is a small wearable sensor that measures glucose continuously and sends readings to a phone or receiver. Modern CGMs are accurate enough to replace most fingerstick testing. Benefits include:

• Real-time glucose visibility and trend arrows
• High and low alerts (particularly valuable for preventing nighttime lows)
• Ambulatory glucose reports showing time in range, patterns, and variability
• Documented improvements in HbA1c and time in range with reduced hypoglycemia

CGMs are indicated for all people with Type 1 diabetes and for many with Type 2, especially those on insulin. Coverage is well established for insulin users and expanding for others.

An insulin pump delivers continuous background insulin plus meal doses through a small subcutaneous cannula. When connected to a CGM and an algorithm, it becomes an automated insulin delivery (AID) system (hybrid closed-loop) that adjusts insulin automatically based on glucose readings.

AID systems represent the current state of the art in insulin delivery:

• Significantly more time in range with fewer lows
• Reduced mental burden of constant dosing decisions
• Particular benefit overnight and during unpredictable activity
• The user still announces meals and makes some decisions, but the algorithm handles most basal adjustments

These systems require training, ongoing support, and a willingness to learn the technology. Coverage is improving but out-of-pocket costs without coverage remain substantial.

• Eversense 365 — a one-year implantable CGM. FDA-cleared in September 2024, this is the first glucose sensor designed to last a full year. A small sensor is placed just under the skin of the upper arm by a clinician, and a removable transmitter sits on top; it can also feed automated insulin delivery systems.
• iLet Bionic Pancreas — an AID with no carbohydrate counting. FDA-cleared in 2023, the iLet (Beta Bionics) is initialized from your body weight alone and asks only for a rough meal size (less / usual / more) rather than carbohydrate counts — a major simplification for many people.
• More interoperable systems. The Sequel twiist (cleared 2024, Tidepool-powered) is an automated insulin delivery system that can pair with the Eversense 365 sensor. Medtronic's MiniMed Go app (cleared January 2026) links a smart insulin pen to a sensor for people on multiple daily injections, bringing dose reminders and a bolus calculator to pen users.

Device availability and insurance coverage vary; your diabetes team can advise on what fits your situation.

Teplizumab is an anti-CD3 monoclonal antibody that modulates the immune attack on beta-cells. The landmark TN-10 trial showed that a single 14-day infusion course delayed the progression from Stage 2 (autoantibodies + abnormal glucose tolerance but no clinical diabetes) to Stage 3 (clinical Type 1 diabetes) by a median of about 2 years. Some participants were delayed much longer.

Teplizumab is approved for people aged 1 and older who are at Stage 2 (the age range was expanded from 8+ down to 1+ in April 2026). In June 2026 the FDA also approved it (accelerated approval) for children and teens aged 8–17 who are newly diagnosed with Stage 3 Type 1 diabetes, to slow the loss of the body's own insulin production. It is given as an infusion course through specialized centers. The treatment is expensive and authorization can be complex — the route to it is a referral from the diabetes team.

• Teplizumab (PROTECT trial, NCT03875729): In this trial teplizumab preserved the body's own insulin production when given shortly after a Stage 3 (clinical) Type 1 diagnosis in children and teens aged 8–17. On this basis the FDA granted accelerated approval in June 2026 for newly-diagnosed Stage 3 patients aged 8–17 (this is a different use from the Stage 2 delay above).
• Verapamil: A common blood-pressure medicine that in early trials showed preservation of beta-cell function and reduced insulin needs when started soon after Type 1 diagnosis.
• Baricitinib (BANDIT trial): An oral JAK inhibitor that, in the Phase 2 BANDIT trial, preserved the body's own insulin production and improved glucose control. On that basis, two Phase 3 trials began in 2026 — one to delay Type 1 in at-risk people and one to preserve beta-cells in newly diagnosed patients. If positive, it could become the first daily oral disease-modifying therapy for Type 1.

These are specialist-level decisions. For anyone recently diagnosed with Type 1, or at high risk, it is reasonable to ask whether any of these options or relevant clinical trials apply.

Beyond teplizumab, many treatments aimed at calming the immune attack on beta-cells are in trials. None is a cure, but several have preserved insulin production in studies:

• Ustekinumab — a psoriasis/Crohn's antibody (anti–IL-12/23) that, in a Phase 2 trial in adolescents, preserved about 49% more of the body's own insulin at one year (published in Nature Medicine, 2024).
• Diamyd (a GAD-based immune therapy) — a precision approach for the ~40% of people with a particular gene type (HLA DR3-DQ2); its Phase 3 trial (DIAGNODE-3) reached an interim analysis in 2026.
• Anti-thymocyte globulin (low-dose ATG; MELD-ATG) — a short immune-resetting course that reduced beta-cell loss in a 2025 trial.
• Golimumab (anti-TNF) and low-dose IL-2 (which boosts protective regulatory T-cells) — both showed signals of beta-cell preservation in earlier studies.

What hasn't worked: in an at-risk prevention trial, abatacept did not delay progression at the earliest (Stage 1) stage — a reminder that timing and patient selection matter.

In June 2023, the FDA approved donislecel (Lantidra) — a donor-derived islet cell therapy for adults with Type 1 diabetes who cannot achieve target HbA1c because of repeated episodes of severe hypoglycemia despite intensive management. Donor islet cells are infused into the liver, where they can produce insulin.

This is not a routine treatment. It requires lifelong immunosuppression to prevent rejection, which carries its own serious risks. In clinical studies, some recipients achieved insulin independence for years, while others did not. Lantidra is reserved for severe, difficult-to-manage Type 1 diabetes where the risks of immunosuppression are judged to be outweighed by the dangers of recurrent severe hypoglycemia. The decision is made through a specialist transplant center.

Lantidra uses islet cells from organ donors, which are always in short supply. The biggest recent breakthrough is making insulin-producing islet cells in the lab — an essentially unlimited supply.

• Zimislecel (VX-880, Vertex) — islet cells grown from stem cells and infused into the liver. In a trial reported in the New England Journal of Medicine in June 2025, 10 of 12 people (83%) no longer needed insulin at one year, and all had major improvements in blood-sugar control. A Phase 3 trial (FORWARD) is enrolling. It still requires immunosuppression — but it is the first manufactured (non-donor) islet therapy to reach this stage.
• Removing the need for immunosuppression. Sana Biotechnology's UP421 uses gene-edited “hypoimmune” islet cells designed to hide from the immune system; an early study reported insulin production for over a year without any immunosuppression — an important proof of concept.
• Gentler anti-rejection drugs. In islet transplants using the antibody tegoprubart (in place of standard calcineurin-inhibitor drugs), an update presented in March 2026 reported all 12 of 12 patients off insulin, with no kidney toxicity.
• Implantable pouches. The Sernova Cell Pouch — a small device implanted under the skin to hold islet cells — reported 8 of 12 patients insulin-independent (2025).

These approaches are investigational and available only through clinical trials, but together they point toward a future functional cure for Type 1 diabetes. (An earlier “encapsulation” approach meant to avoid immunosuppression — Vertex's VX-264 — was discontinued in 2025 after it did not produce enough insulin.)

Insulin icodec (Awiqli) is a basal insulin designed to be injected once per week instead of once daily. Phase 3 trials (ONWARDS program) showed non-inferior glucose control compared to daily basal insulins. It is approved by the EMA (2024) and, as of March 2026, by the US FDA for adults with Type 2 diabetes. It is not approved for Type 1 diabetes in the US (the FDA declined the Type 1 use over hypoglycemia concerns).

Once-weekly dosing may reduce injection burden and improve adherence, particularly for people who find daily injections difficult. However, the longer duration means that dose adjustments take longer to take effect, and episodes of hypoglycemia may require different management. This is a question to raise with the diabetes team as availability expands.

• Insulin efsitora alfa — a second once-weekly basal insulin, with a different design from icodec (a roughly 17-day duration and fixed-dose titration). Its Phase 3 program (QWINT) is complete and matched daily insulin for glucose control; it has been submitted to the FDA with a decision pending. If approved, people would have two weekly-insulin choices.
• Once-weekly insulin + GLP-1 in one injection (Kyinsu / IcoSema) — a fixed combination of insulin icodec and semaglutide, approved in the European Union (late 2025) for type 2 diabetes. It is not approved in the US (the FDA declined the icodec component in 2024).
• Insulin biosimilars — lower-cost versions of rapid-acting insulin aspart are now FDA-approved: Merilog (February 2025) and Kirsty (July 2025, the first interchangeable aspart biosimilar). These can reduce out-of-pocket cost at the pharmacy.

LADA is a slowly progressing autoimmune diabetes often misdiagnosed as Type 2. Key features:

• Diagnosed in adults (typically over 30), often leaner than typical Type 2
• Positive for autoantibodies (especially GAD), with initially preserved C-peptide
• Initially manageable without insulin, but progresses to insulin dependence over months to years
• Sulfonylureas may accelerate beta-cell loss and are generally avoided
• Early insulin is often the best approach once the diagnosis is clear

An estimated 5–15% of adults diagnosed with Type 2 actually have LADA. If treatment isn’t working as expected, antibody testing should be considered.

MODY is a group of monogenic (single-gene) diabetes forms, each with its own behavior:

• GCK-MODY: Mildly raised glucose from birth; typically needs no treatment at all — a life-changing diagnosis for people who have been treated unnecessarily.
• HNF1A-MODY: Responds dramatically to low-dose sulfonylurea — often better than insulin and far simpler.
• HNF4A-MODY: Similar to HNF1A; sulfonylurea-responsive.

MODY accounts for 1–2% of diabetes. The Exeter MODY probability calculator helps guide referral for genetic testing. Correct diagnosis can completely transform treatment.

• Ketosis-prone diabetes (“Flatbush diabetes”): Presents like Type 1 with DKA but may later behave like Type 2, sometimes with periods off insulin. More common in people of African, Hispanic, and Asian descent.
• Secondary diabetes: Caused by other conditions or treatments — pancreatitis, cystic fibrosis, steroid use, organ transplant medicines. Treatment depends on the underlying cause.
• Neonatal diabetes: Diagnosed under 6 months of age — almost always a single-gene (monogenic) condition, not ordinary Type 1. Genetic testing is essential and can transform treatment: most babies with the common KCNJ11 or ABCC8 gene changes can switch off insulin injections onto a sulfonylurea tablet with excellent control, while those with an INS gene change need insulin. It is one of the clearest examples of precision medicine in diabetes.

1. Get the right tests and confirm where you stand. HbA1c, fasting glucose, weight, waist, blood pressure, and lipids.
2. Join a structured prevention program. A recognized Diabetes Prevention Program is the single best-evidenced step.
3. Build the activity habit, including resistance training. 150 min/week moderate activity + 2–3 strength sessions.
4. Choose an eating pattern you can keep. Mediterranean, lower-carb, or plant-predominant — whichever you’ll sustain.
5. Protect your sleep and address stress. 7–9 hours; screen for sleep apnea if indicated.
6. Discuss whether medicine belongs in your plan. Metformin or GLP-1 alongside lifestyle for higher-risk individuals.

1. Confirm your diabetes type and act on the remission window. The years right after diagnosis are the highest-yield time.
2. Choose a structured weight-loss route and commit. TDR, GLP-1/dual agonist + lifestyle, or surgery. Pick the one that fits.
3. Make medication changes safe. Any push toward remission means supervised medicine reduction.
4. Add resistance training and enough protein. Protect muscle during weight loss.
5. Set up cardiovascular and kidney protection. Blood pressure, cholesterol, and organ-protective medicines matter even with remission as the goal.
6. Plan maintenance from the start. Ongoing support and a weight-regain rescue plan while motivation is high.
7. Screen for and treat diabetes distress and depression. Your emotional health drives whether everything else happens.

1. Confirm the diagnosis precisely. Antibodies, C-peptide, and genetic testing where MODY is suspected.
2. Get on CGM and automated insulin delivery if you use insulin. The single largest improvement available for most people on insulin.
3. Build time in range, not just a lower HbA1c. Aim for > 70% time in range while keeping lows to < 4%.
4. Ask about disease-modifying and beta-cell-preserving options. Teplizumab, verapamil, or relevant trials.
5. Put psychosocial and family support in place. Distress, burnout, school plans, and caregiver support are core care.
6. Keep complication screening on schedule. Eyes, kidneys, feet, and cardiovascular checks at set intervals.

• What type of diabetes do I have, and how confident are you in that classification?
• Have I had antibody testing and a C-peptide measurement? Should I?
• Do any features suggest LADA, MODY, or another rare form worth testing for?
• How long do you estimate I have had diabetes, and what does that mean for my options?

• What HbA1c, time-in-range, blood pressure, and cholesterol targets are right for me, and why?
• How are my kidneys, and what is my cardiovascular risk?
• Which of my numbers most needs attention first?

• What is each of my medicines for, and what should I watch for?
• Do I have a condition (heart, kidney, liver) that means a particular medicine class would protect me?
• Are any of my medicines causing side effects we could address or substitute?
• If my situation improved, which medicines could be reduced, and how?

• Am I a candidate to pursue remission? What do my duration and beta-cell reserve suggest?
• Which weight-loss route — TDR, medication + lifestyle, or surgery — fits me best?
• Is there a structured program you can refer me to?
• How will my medicines be adjusted as I lose weight, and how will we prevent lows?
• What is the maintenance plan, and what happens if I regain weight?

• Am I eligible for a continuous glucose monitor? Would it help me even if I am not on insulin?
• If I use insulin, am I a candidate for an automated insulin delivery system?
• When are my next eye, kidney, and foot checks due?
• Are there any early signs of complications in my results?
• I have been feeling overwhelmed or low — what support is available?
• Can you refer me to a diabetes educator, dietitian, or behavioral health professional?
• What is the one change that would make the biggest difference right now?
• Are there clinical trials or newer options I should know about?

• Repeated low blood sugars — especially severe, nocturnal, or without warning. This is fixable.
• Blood sugars running high for several days — especially with illness, steroids, or unusual stress.
• Signs of ketoacidosis (DKA) — nausea, vomiting, abdominal pain, rapid breathing, fruity breath. This is urgent.
• Weight regain after remission — act when weight begins creeping up, before blood sugar rises.
• HbA1c drifting above target or above the remission threshold.
• New or worsening symptoms — vision changes, foot numbness/pain, swelling, chest symptoms, slow-healing wounds.
• Side effects from a medicine that are hard to live with — alternatives usually exist.
• Emotional signals — burnout, skipping care, persistent low mood, or any thoughts of self-harm.
• Major life changes — pregnancy, new job, new diagnosis, a move.

This guide gives you the vocabulary, the questions, and the landscape of options. But the actual decisions belong to you and the professionals who know your case. The steps:

1. Gather your own data: Diabetes type and duration, recent HbA1c and CGM data, weight history, current medicines and side effects, blood pressure/cholesterol/kidney/liver results, most recent eye and foot exam dates, and an honest note on how you are doing emotionally.
2. Assemble the right team: Primary care doctor or endocrinologist, diabetes educator, registered dietitian, and — when needed — behavioral health, exercise, kidney, eye, foot, or genetics specialists. Build around the questions in front of you.
3. Define what success means to you: For one person the priority is remission; for another, fewer lows; for a parent, a child who can be a child. Share your priorities plainly with your team.
4. Decide, act, and review: Choose a small number of changes, act on them, review at a set interval. The first plan is rarely the final one. Adjusting is success, not failure.

People of South Asian, East Asian, and several other backgrounds tend to develop insulin resistance and ectopic fat at lower body weights. Guidelines use lower BMI thresholds: screening often from BMI 23 rather than 25, and metabolic surgery consideration at lower cutoffs. The practical message: be screened earlier and at a lower weight, and do not be falsely reassured by a “normal” BMI alone.

Two questions are always reasonable: “Given my ancestry, should I be screened or treated at a lower weight threshold?” and “What structured programs for prevention or remission are available where I live?”

Diabetes is now one of the world's most common diseases — the International Diabetes Federation's 2025 Atlas counts about 589 million adults living with it (roughly 1 in 9), projected to reach 853 million by 2050. New treatments are arriving at different speeds in different countries:

• United States: the ADA's 2026 Standards now advise offering continuous glucose monitoring at or near diagnosis for many people, a stricter blood-pressure goal (under 120) for those at high heart/kidney risk, and a GLP-1 medicine when fatty-liver disease (MASH) is also present. Semaglutide (Ozempic) gained a kidney-protection indication in early 2025.
• United Kingdom: NICE's updated NG28 guideline (2026) now recommends starting an SGLT2 inhibitor together with metformin from diagnosis for many people, rather than waiting for blood sugar to worsen. The UK (2025) also approved teplizumab to delay Type 1 diabetes.
• China: regulators approved several first-in-class medicines ahead of much of the world, including mazdutide (a dual gut-hormone weight/diabetes drug) and cofrogliptin (the first twice-monthly pill of its class).
• Japan, Canada, Australia: Japan approved tirzepatide for obesity (late 2024); Canada approved teplizumab for Type 1 delay (2025); Australia approved semaglutide for kidney protection (2025).

If a treatment you've read about isn't available where you live yet, it's worth asking your team what equivalent options are approved locally.

A meta-analysis of 26 randomized controlled trials enrolling 1,625 participants examined the effect of fenugreek supplementation on glycemic markers in people with diabetes or prediabetes.

What this means: The HbA1c reduction (-0.63%) is clinically meaningful and comparable to some oral diabetes medications. Fenugreek has a long history of use in South Asian and Middle Eastern traditional medicine.

Safety considerations: Fenugreek can lower blood glucose, which means it may add to the effect of diabetes medicines and increase the risk of hypoglycemia. It may also affect the absorption of other oral medications. Always inform your medical team if you are taking or considering fenugreek.

Source: PMC12777671 — Meta-analysis of 26 RCTs, 1,625 participants

A meta-analysis of 17 randomized controlled trials published in Phytotherapy Research (2019) examined the glycemic effects of Nigella sativa (black seed) supplementation.

What this means: The HbA1c reduction is statistically significant and clinically relevant. Nigella sativa has been used for centuries in Middle Eastern, South Asian, and African traditional medicine systems.

Safety considerations: Like fenugreek, Nigella sativa can lower blood glucose and may increase hypoglycemia risk when combined with diabetes medicines. It may also interact with medications metabolized by liver enzymes. Discuss with your medical team before use.

Source: PubMed 30873688 — Phytotherapy Research, 2019; meta-analysis of 17 RCTs

A meta-analysis of 14 randomized controlled trials involving 1,876 participants, published in the Journal of Diabetes and Metabolic Disorders (2025), examined the effect of yoga practice on glycemic control.

What this means: Yoga practice produced a statistically significant reduction in HbA1c. The benefit likely comes from a combination of physical activity, stress reduction (cortisol lowers insulin sensitivity), and improved sleep. Yoga is safe for most people, low-cost, and can be adapted for different physical abilities.

Practical note: Yoga works best as an addition to aerobic and resistance exercise (see the Exercise section above), not a replacement. Even gentle forms such as chair yoga may have benefit, particularly for stress and cortisol management.

Source: PubMed 41328441 — Journal of Diabetes and Metabolic Disorders, 2025; meta-analysis of 14 RCTs, 1,876 participants

An umbrella review of multiple systematic reviews covering dozens of randomized controlled trials, published in PLOS ONE (2023), examined the effect of curcumin supplementation on glycemic markers in people with diabetes and prediabetes.

What the evidence shows: The umbrella review found that curcumin supplementation was associated with improvements in fasting blood glucose, HbA1c, and insulin resistance markers (HOMA-IR). However, the quality of the underlying evidence varied considerably across the included reviews, and many of the individual trials were small and short in duration.

Safety considerations: Curcumin has poor bioavailability on its own; most supplements add piperine (black pepper extract) to improve absorption. Curcumin inhibits platelet aggregation and should be used cautiously with blood thinners. It can also cause GI upset. As with all glucose-lowering supplements, it may add to the effect of diabetes medicines.

The honest picture: There is a genuine signal of benefit for glycemic markers, but the evidence is not yet strong enough or consistent enough to recommend curcumin as a standard part of diabetes care. It is reasonable to discuss with your medical team as an adjunct.

Source: PLOS ONE, 2023 — Umbrella review of systematic reviews with meta-analyses covering dozens of RCTs

• Cinnamon: Very small glucose effect in some studies. Prefer Ceylon cinnamon; cassia contains coumarin (liver risk at high intake).
• Bitter melon & gymnema: Traditional remedies with small studies suggesting modest effects.
• Omega-3 fatty acids: Don’t lower glucose directly, but can reduce triglycerides.
• Probiotics: Active research area; some studies show small HbA1c effect depending on strains.
• Coenzyme Q10: Sometimes used alongside statins; any glucose effect is small.

• Very high-dose chromium (kidney concerns)
• Vanadium (narrow margin between usual and toxic dose)
• Any product marketed as a diabetes “cure,” a “natural insulin,” or a replacement for prescribed medicine — these claims are a reliable signal to walk away

• Rosiglitazone (Avandia) — Once one of the most widely prescribed diabetes medicines, rosiglitazone was severely restricted in 2010 after a meta-analysis linked it to increased heart attack risk. Although later FDA review partially lifted restrictions (2013), the drug never recovered clinical confidence and is rarely used today. Pioglitazone, from the same class, does not share this signal. WITHDRAWN from common use
• Inhaled insulin (Exubera) — Pfizer launched Exubera in 2006 as the first inhaled insulin, but it was withdrawn in 2007 due to extremely poor sales, a bulky delivery device, concerns about lung function monitoring requirements, and a signal of increased lung cancer risk. A later inhaled insulin (Afrezza) was approved in 2014 with a smaller device but has seen limited uptake. FAILED commercially
• Tight glucose control in critically ill patients (intensive insulin therapy) — Early studies suggested that targeting near-normal blood sugars (80–110 mg/dL) in ICU patients improved survival. The large NICE-SUGAR trial (2009) showed the opposite: intensive glucose control in critically ill patients increased mortality compared to a more moderate target (140–180 mg/dL). ICU glucose management was fundamentally changed as a result. DE-ADOPTED
• Sliding-scale insulin alone (for inpatients) — For decades, hospitalized patients with diabetes were managed with reactive, sliding-scale-only insulin — giving insulin only after blood sugar was already high, with no scheduled background or mealtime doses. The RABBIT-2 trial (2007) and subsequent evidence showed that scheduled basal-bolus insulin is superior. Sliding-scale-only management is now considered substandard care. DE-ADOPTED
• Aggressive HbA1c targets in established Type 2 (ACCORD trial) — The ACCORD trial (2008) tested whether driving HbA1c below 6.0% in people with longstanding Type 2 diabetes and cardiovascular risk would reduce heart events. The intensive-treatment arm was stopped early because of increased mortality, likely from severe hypoglycemia. This result shifted guidelines toward individualized targets rather than a one-size-fits-all approach. FAILED
• Saxagliptin for cardiovascular benefit (SAVOR-TIMI 53) — Saxagliptin, a DPP-4 inhibitor, was tested in a large cardiovascular outcomes trial. It did not reduce cardiovascular events and was associated with a statistically significant increase in heart failure hospitalizations. This led to preferring sitagliptin or linagliptin within the DPP-4 class and to the broader recognition that DPP-4 inhibitors do not provide cardiovascular benefit. FAILED to show benefit; safety signal
• Alpha-glucosidase inhibitors as primary therapy in the West — Acarbose and miglitol, which slow carbohydrate digestion, were once promoted as first-line options. Their modest glucose-lowering effect, significant gastrointestinal side effects (gas, bloating, diarrhea), and the availability of better-tolerated and more effective alternatives have pushed them out of routine Western practice. They remain more commonly used in East Asian countries. DE-ADOPTED in most Western guidelines

• CGMs and insulin pumps: Prescribed devices; coverage well established for insulin users, expanding for others. Denials are frequently overturned on appeal.
• GLP-1 / dual agonist medicines: Prior authorization is common. Manufacturer savings programs exist. Without coverage, costs are substantial.
• Total diet replacement programs: Availability varies; NHS-funded in the UK (Path to Remission). Elsewhere, ask about structured options.
• Metabolic surgery: Multidisciplinary evaluation required. Coverage common when criteria are met.
• Genetic testing (MODY): Specialist referral; increasingly covered when criteria are met.
• Teplizumab: Specialty infusion through specialized centers; expensive; complex authorization.
• Education, dietitians, behavioral health: Frequently covered with referral; available by telehealth. Among the most underused parts of diabetes care.

• It does not know you. Your diabetes type, duration, remaining beta-cell function, other conditions, medicines, finances, family situation, and what matters most to you — all of these change what the right plan is. Where this guide and your team differ, your team is the authority.
• It is not medical advice. Nothing here should be acted on — especially anything involving medicines, insulin doses, or major dietary changes — without the involvement of qualified professionals.
• It may be out of date in places. Diabetes care moves quickly. Specific details may have changed since this guide was written. Verify time-sensitive claims with your team.
• It cannot promise outcomes. It describes what is possible and what improves the odds. It cannot guarantee remission, avoidance of complications, or that any plan will work for any individual.
• It does not cover everything. Insulin dosing details, full complication management, pregnancy specifics, every rare form, and the newest experimental therapies are beyond a single guide’s scope.